Effective tracking and monitoring of polymer-based biodegradable stents (BDSs) in vivo is crucial for their successful application in treating cardiovascular diseases.However, the lack of radiopacity in BDSs poses significant challenges in accurately monitoring the progress of the patient condition.To address this limitation, we propose the incorporation of a biodegradable contrast agent called PCL-TIB.PCL-TIB is synthesized by coupling 2,3,5-triiodobenzoic acid (TIB) with polycaprolactone diol (PCL-diol).The resulting PCL-TIB is then blended with polycaprolactone (PCL) to create a polymer matrix suitable for stent fabrication using additive manufacturing techniques.The mech. stability of the fabricated BDSs is evaluated through comprehensive analyses, demonstrating that the BDSs can withstand external forces and effectively retain their structural integrity.The cell viability of human umbilical vein endothelial cells HUVECs on the proposed BDSs exceeds 90% compared to the cell viability of the control group, signifying the excellent biocompatibility and cytotoxicity of the fabricated BDSs.Furthermore, in vivo X-ray visibility anal. of the fabricated BDSs, including those containing iohexol, reveals a decrease in radiopacity after 7 days, with no discernible X-ray radiopacity observed after 9 days.In contrast, BDSs incorporating the proposed biodegradable contrast agent maintain their X-ray radiopacity for up to 42 days, representing a significant achievement compared to previously reported radiopaque BDSs.Based on the results obtained, we believe that the fabricated BDSs exhibit excellent mech. stability, biocompatibility, and extended radiopacity, making them promising candidates for the treatment of various cardiovascular diseases.